[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Nov 2005

Shimizu Junichi, Horio Yoshitsugu, Mitsudomi Tetsuya

Abstract excerpt

Gefitinib (Iressa, ZD 1839) is an orally bioavailable small molecule that selectively inhibits epidermal growth factor receptor(EGFR) tyrosine kinase activity. Gefitinib causes a dramatic response in approximately 10% to 20% of patients with non-small-cell lung cancer (NSCLC) who receive prior ch...

Topics

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Cisplatin
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Deoxycytidine
ErbB Receptors
Female
Gefitinib
Genes, erbB-1
Humans
Lung Neoplasms
Male
Mutation
Paclitaxel
Quinazolines
Survival Rate

Source

Open in PubMed

Identifiers

PMID: 16282720

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-16282720-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics